Blood Group Typing Market

Blood Group Typing Market Size (2023 to 2028)

The global blood group typing market size is predicted to be worth USD 5.03 billion by 2028 from USD 3.14 billion in 2023. This market showcases a CAGR of 9.9% during the forecast period.

Through laboratory testing, blood group typing distinguishes and classifies a person's blood group into one of the groups (such as A, B, or O). Transfusing blood, testing donor blood matching with the recipient patient, and determining Rh factor all require a blood group typing test. Since not all blood groups are compatible, knowing the blood group is crucial. Blood typing aids in the diagnosis of hemolytic disease of the newborn (HDN) in pregnant mothers, resulting in an increase in the market for these examinations. Receiving blood that isn't consistent with a person's blood type (blood with foreign antigens) can cause a harmful immune reaction (by creating antibodies against the foreign antigen).

The global pandemic has presented unprecedented challenges to the blood group typing market in 2020. When it comes to receiving a blood transfusion, accurate blood grouping is essential. The nature and presence of antigens in red blood cells play a role in blood group identification. During a blood transfusion or organ transplant treatment, blood group typing is a critical examination that helps determine the donor's similarity to the recipient. Improvements aided the market's development in the blood detection technique. According to the American National Red Cross, almost 21 million blood products are transfused per year in the United States. According to the same article, nearly 6.8 million individuals in the United States donate blood each year.

MARKET DRIVERS:

Y-O-Y growth in the number of blood banks worldwide, increased blood donors, blood donation campaigns, and blood transfusions across the globe are expected to boost the global blood group typing market.

Increasing prevalence to identify an individual's blood group in the medical sector is a key driving factor for the blood group typing market to grow. The growing number of blood banks across the world is accelerating the demand of the market. Besides, increasing accidental cases and blood in emergency cases propel the need for the blood group typing market. Rising incidences of chronic diseases and the growing number of surgical treatment procedures greatly influence the growth of the global blood group typing market. Even in rural areas, increasing blood donation campaigns is gearing up the demand of this market. The emergence of the latest technologies in the medical sector is to set up growth opportunities for the market.

Furthermore, the market benefits from an increase in the number of traffic crashes and injuries, and an increase in the number of blood checks for blood transfusion improves the market growth. Blood transfusions and organ replacement have risen as the number of blood tumors such as lymphoma, leukemia, and myeloma, and blood-related diseases have increased. However, improving healthcare infrastructure in developing markets such as China and India are expected to propel the market growth. The market is expected to expand further as more of these tests diagnose Hemolytic Disease of the Newborn (HDN).

Also, a rising number of healthcare facilities and the advances in blood group typing systems, on the other hand, create promising growth opportunities for market participants, which is likely to augment the market growth. Another important factor driving the market growth is the growing relevance of blood group typing during pregnancy. The rising prevalence of chronic diseases, as well as increased R&D initiatives aimed at understanding the molecular basis of blood and antibody-antigen interactions, can be credited for this segment's large share and rapid development.

MARKET RESTRAINTS:

However, the negligence of the staff members in maintaining correct formats is quietly hindering the demand of the blood group typing market. The cost of installing and maintaining the devices is a little expensive, which remained a challenging factor for the market developers.

Impact of COVID-19 on the global blood group typing market:

The Emergence of the global pandemic COVID-19 has affected the different sectors of the economy. The COVID-19 epidemic has resulted in a significant drop in voluntary blood donors worldwide, owing to concerns about the equipment's safety requirements and the imposition of lockdowns in most countries. Many countries' health services have begun to sound the alarm as the available blood supply has declined. For instance, the UK's National Health Service (NHS) reported in March 2020 that voluntary donations fell by 15%. In India, the Rotary Blood Bank and the Indian Red Cross Society announced that blood donation was at an all-time low, with a staggering 80 percent shortfall. Patients with thalassemia and hemophilia, which undergo daily blood transfusions, are likely to suffer unfathomable consequences from such unexpected drops in blood donations. Since the effectiveness of blood typing systems is highly reliant on blood donors, a decrease in these operations would have a negative impact on the development of the blood group typing market.

REPORT COVERAGE:

This report on the global blood group typing market has been segmented and sub-segmented based on technique, product type, test type, end-user, and region.

Blood Group Typing Market - By Product:

• Consumables
• Instruments
• Services

Based on the product, the consumables segment holds the largest market share value due to the growing increase of surgical processes and usage of laboratories.

Blood Group Typing Market - By Technique:

• PCR-based and Microarray Techniques
• Assay-based Techniques
• Massively Parallel Sequencing Techniques
• Other Techniques

Based on the technique, the PCR-based and Microarray Techniques segment is likely to hold the largest market share value of Blood Group Typing due to the growing aged people population and the number of people increasing with different kinds of health issues.

Blood Group Typing Market - By Test Type:

• Antibody Screening
• HLA Typing
• Cross-Matching Tests
• ABO Blood Tests
• Antigen Typing

Based on the Test Type, the Antibody screening segment is expected to have an important growth during the period, which is attributed to the growing demand for quick diagnosis of the diseases that are suffering, producing maximum advantages for the growth during the rate.

Blood Group Typing Market - By End-User:

• Hospitals
• Blood Banks
• Clinical Laboratories
• Others

Based on the end-user type, the hospital segment is likely to have an intense growth due to more knowledge about the blood group.

Blood Group Typing Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Based on the region, the North American region holds the most significant shares in the global blood group typing market with the rise in the capital income in most countries. The launch of various new techniques in the medical sector to enable easy identification of blood groups is bolstering the demand of this market.

With the increasing population and rise in applications in forensic sciences to identify the blood group from samples collected. The Middle East and Africa to have an inclined growth rate in coming years.

KEY MARKET PARTICIPANTS:

Some of the promising leading the global blood group typing market profiled in the report are Bio-Rad Laboratories, Inc., Grifols, S.A., Immucor Inc., Ortho Clinical Diagnostics, Inc., Quotient, Ltd., Novacyt Group, BAG Healthcare GmbH, Rapid Labs, Day medical SA, DIAGAST, and AXO Science.

Recent Developments in the Blood Group Tying Market:

• Product Initiative - In 2017: The Philippines launched a free blood group typing scheme. In this initiative, it is easy to identify possible blood donors through times of disease outbreak, and the title of this campaign was "Type ng Bayan" sponsored by health government departments along with the collaboration of DU30 cabinet spouses.
• Product Approval - In late 2016: The U.S. Food and Drug Administration (FDA) approved Immucor's Precise Type HEA test and its use to identify sickle cell characteristics in blood donors. Many regulatory agencies, such as the FDA, are involved in developing and applying uniform access to reliable blood policies at the country level.
• Acquisition - In Jan 2017: Grifols has completed the acquisition of Hologic 2017. This acquisition company mainly focussed on research, production, assay manufacturing, NAT (Nucleic Acid Testing) technology-based instruments for transfusion and transplantation screening.
• In June 2014, Carlyle Group bought Ortho-Clinical Diagnostics, Inc. for about USD 4 billion in late 2014. Through this purchase, the business has invested in Research and Development throughout the world for medical diagnostic products and services.
• Acquisition - In 2014: Immucor, Inc., a world leader in diagnostics for transfusion and transplantation, confirmed its acquisition of Mountain View, Sirona Genomics (Sirona), headquartered in CA, at the end of 2014. Under this, Immucor aimed to provide research funding to support the promotion of Sirona's HLA model sample preparation and bioinformatics service using leading NGS methods.